Publikationen in Zusammenarbeit mit Forschern von University of Zurich (60)

2024

  1. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 10, pp. 2648-2668.e2

  2. Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 5, pp. 1089-1122

2023

  1. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 11, pp. 2851-2874

  2. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

  3. Tonsillar transcriptional profiles in atopic and non-atopic subjects

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 2, pp. 522-536

  4. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs

    Nature Reviews Drug Discovery, Vol. 22, Núm. 9, pp. 743-767

2022

  1. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 8, pp. 2313-2336

  2. Cannabinoid WIN55212-2 impairs peanut-allergic sensitization and promotes the generation of allergen-specific regulatory T cells

    Clinical and Experimental Allergy, Vol. 52, Núm. 4, pp. 540-549

  3. Cannabinoids induce functional Tregs by promoting tolerogenic DCs via autophagy and metabolic reprograming

    Mucosal Immunology, Vol. 15, Núm. 1, pp. 96-108

  4. EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 1, pp. 17-38

  5. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 8, pp. 2337-2354

  6. Mechanismen bei AIT: Erkenntnisse 2021

    Allergologie, Vol. 45, Núm. 12, pp. 848-856

  7. The cannabinoid WIN55212-2 suppresses effector T-cell responses and promotes regulatory T cells in human tonsils

    Allergy: European Journal of Allergy and Clinical Immunology

2021

  1. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy

    Clinical and Translational Allergy, Vol. 11, Núm. 4

  2. Biologicals in atopic disease in pregnancy: An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 71-89

  3. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 648-676

  4. Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 114-130

  5. EAACI Biologicals Guidelines—Recommendations for severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44

  6. EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 4, pp. 988-1009

  7. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 6, pp. 1629-1639